Parkinson’s Disease in Major Markets, Disease Management, Epidemiology, Pipeline Assessment, Unmet Needs and Drug Forecast 2029

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

$10995
Buy Report View Sample

Published: July 12, 2023 Report Code: GDHC276PIDR-ST

Select Item

Parkinson’s Disease Market Overview

Parkinson’s Disease market size across the 7MM was valued at $3.4 billion in 2019 and is expected to achieve a CAGR of more than 6% during 2019-2029. The US is the most significant contributor to that revenue mainly due to the cost of drugs, which is significantly higher in the US compared to other countries in the 7MM.

Parkinson’s Disease Market Outlook, 2019-2029 ($ Billion)

Parkinson’s Disease Market Outlook, 2019-2029 ($ Billion)

To gain more information on the Parkinson’s Disease market forecast, download a free report sample

The Parkinson’s Disease market research report provides a forecast model for the Parkinson’s Disease market through 2029 as well as an overview of the disease, including epidemiology, symptoms, diagnosis, and disease management.

Market Size (2022) $3.4 billion
CAGR (2022 – 2032) >6%
Forecast Period 2019-2029
Key Countries ·       The US

·       France

·       Germany

·       Italy

·       Spain

·       United Kingdom

·       Japan
Leading Players ·       AbbVie

·       UCB

·       Amneal Pharmaceuticals

·       Supernus Pharmaceuticals

·       Acadia

·       Kyowa Kirin

·       Others
Enquire & Decide Discover the perfect solution for your business needs. Enquire now and let us help you make an informed decision before making a purchase.

Parkinson’s Disease Market Dynamics

The number of diagnosed prevalent cases of PD will increase, mainly due to the growing aging population across the 7MM over the next 10 years. Drugs that are approved for niche population will gain label extensions in broader patient population, allowing them to expand their target patient pool. Several pipeline products will launch, most notably Annovis Bio’s Buntanetap, BioVie’s NE-3107, Neuraly’s NLY01, and Roche/Prothena’s prasinezumab, which are being investigated for their disease-modifying or neuroprotective properties. However, several leading drugs in the market will experience patent expiry. This will lead to the erosion of branded drug sales as the market floods with cheaper generic versions. Furthermore, the high use of inexpensive generic products is expected to continue throughout the forecast period. The lack of validated predictive biomarkers of PD progression has made the development of disease-modifying therapies and neuroprotective agents challenging.

To know more about the Parkinson’s Disease market dynamics, download a free sample report

Parkinson’s Disease Market Segmentation by Countries

Some of the key countries in the Parkinson’s Disease market are the US, France, Germany, Italy, Spain, the UK, and Japan. The US had the highest share of the market in 2022.

Parkinson’s Disease Market Analysis by Countries, 2019 (%)

Parkinson’s Disease Market Analysis by Countries, 2019 (%)

For more country insights into the Parkinson’s Disease market, download a free report sample

Parkinson’s Disease Market - Competitive Landscape

There is a high level of competition within the PD market. Currently, there are many players involved in the PD market, with several companies responsible for the development of one or two assets across both their marketed portfolio and pipeline. The main players in the market currently are AbbVie (Duodopa), UCB (Neupro), Amneal Pharmaceuticals (Rytary), Supernus Pharmaceuticals (Gocovri), Acadia (Nuplazid), and Kyowa Kirin (Nourianz). A few new entrants to the current market are expected to drive further demand for rescue medications, which will contribute to market growth. These include Sunovion (Kynmobi) and Accorda (Inbrija).

Segments Covered in the Report

Parkinson’s Disease Country Outlook (Value, $ Billion, 2019-2029)

  • The US
  • France
  • Germany
  • Italy
  • Spain
  • The UK
  • Japan

Scope

This report provides:

  • Overview of PD, including epidemiology, symptoms, diagnosis, and disease management.

  • Annualized PD treatment market revenue, cost of therapy per patient, and treatment usage patterns forecast from 2019 to 2029.

  • Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping, and implications of these factors for the PD therapeutics market.

  • Pipeline analysis: comprehensive data assessing emerging trends and mechanisms of action under development for PD treatment. The most promising candidates in Phase III and Phase IIb development are profiled.

  • Analysis of the current and future market competition in the global PD therapeutics market. Insightful review of the key industry drivers, restraints, and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.

Key Highlights

Report deliverables include a PowerPoint report and Excel-based forecast model

Forecasts includes the 7MM

Forecasts covers from 2019-2029

Reasons to Buy

The report will enable you to:

  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.

  • Develop business strategies by understanding the trends shaping and driving the 7MM obesity therapeutics market.

  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the 7MM VTE therapeutics market in the future.

  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.

  • Identify emerging players with potentially strong product portfolios and create effective counterstrategies to gain a competitive advantage.

  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.

AbbVie
Acadia
Acorda Therapeutics
Alkahest
Amneal Pharmaceuticals
Anavex Life Sciences
Annovis Bio
BioVie
Britannia Pharmaceuticals
Cerevel Therapeutics
GSK
Ipsen
IRLAB
Kyowa Hakko Kirin
Luye Pharma
Merck
Neuraly
Neurocrine
NeuroDerm
Newron
Orion
Pharma Two B
PharmaTher Holdings
Prothena
PureIMS
Roche
Sunovion
Supernus Pharmaceuticals
Teva
UCB

Table of Contents

About GlobalData

List of Contents

List of Tables

List of Figures

1 Parkinson’s Disease: Executive Summary – Updated August 2023, Based on Events Up to June 30, 2023

1.1 Parkinson’s market expected to grow significantly, driven by new launches

1.2 Significant opportunities and risks for disease-modifying therapies entering the PD market

1.3 Diverse pipeline agents will partially address key unmet needs

1.4 The advancement of levodopa delivery systems will shape the PD market

1.5 What do physicians think?

2 Introduction – Updated August 2023

2.1 Catalyst

2.2 Related reports

2.3 Upcoming reports

3 Disease Overview – Updated June 2023

3.1 Etiology and pathophysiology

3.1.1 Etiology

3.1.2 Pathophysiology

3.1.3 Mechanisms of cell death

3.2 Classification or staging systems

4 Epidemiology

4.1 Disease background

4.2 Risk factors and comorbidities

4.3 Global and historical trends

4.4 Forecast methodology

4.4.1 Sources

4.4.2 Forecast assumptions and methods

4.5 Epidemiological forecast for PD (2019–29)

4.5.1 Diagnosed prevalent cases of PD

4.5.2 Sex-specific diagnosed prevalent cases of PD

4.5.3 Age-specific diagnosed prevalent cases of PD

4.5.4 Diagnosed prevalent cases of PD by Hoehn and Yahr clinical staging

4.5.5 Diagnosed prevalent cases of PD by type

4.6 Discussion

4.6.1 Epidemiological forecast insight

4.6.2 COVID-19 impact

4.6.3 Limitations of the analysis

4.6.4 Strengths of the analysis

5 Disease Management – Updated June 2023, Based on Events Up to June 30, 2023

5.1 Diagnosis and treatment overview

5.2 Key opinion leader insights on disease management

6 Competitive Assessment – Updated August 2023, Based on Events Up to June 30, 2023

6.1 Overview

7 Unmet Needs and Opportunity Assessment – Updated June 2023, Based on Events Up to June 30, 2023

7.1 Overview

7.2 Effective treatment of motor complications – dyskinesia, off episodes, gait, and balance problems

7.3 New therapies for non-motor complications – psychosis and dementia

7.4 Neuroprotective or disease-modifying agents

7.5 Improved drug formulations

8 R&D Strategies – Updated June 2023, Based on Events Up to June 30, 2023

8.1 Overview

8.1.1 Development of novel targets ─ mAbs targeting α-synuclein and gene therapies

8.1.2 Innovative drug delivery systems

8.1.3 Secondary indications and drug repurposing

8.1.4 Clinical trial design

8.1.5 Reliable biomarkers of disease progression

8.1.6 Genetic studies required to learn about genetic subtypes of PD

9 Pipeline Assessment – Updated June 2023, Based on Events Up to June 30, 2023

9.1 Overview

9.2 Promising drugs in clinical development

10 Pipeline Valuation Analysis – Updated June 2023, Based on Events Up to June 30, 2023

10.1 Overview

10.2 Competitive assessment

10.2.1 Levodopa therapy

10.2.2 Dopamine agonists

10.2.3 Products targeting non-motor symptoms

10.2.4 Non-levodopa therapies

10.2.5 Therapies for levodopa-induced dyskinesia

11 Current and Future Players – Updated June 2023, Based on Events Up to June 30, 2023

11.1 Overview

11.2 Deal-making trends

12 Market Outlook – Updated August 2023, Based on Events Up to June 30, 2023

12.1 Global markets

12.1.1 Forecast

12.1.2 Drivers and barriers – global issues

12.2 US

12.2.1 Forecast

12.2.2 Key events

12.2.3 Drivers and barriers

12.3 5EU

12.3.1 Forecast

12.3.2 Key events

12.3.3 Drivers and barriers

12.4 Japan

12.4.1 Forecast

12.4.2 Key events

12.4.3 Drivers and barriers

13 Appendix

13.1 Bibliography

13.2 Abbreviations

13.3 Methodology

13.3.1 Forecasting methodology

13.4 Primary research – key opinion leaders interviewed for this report

13.4.1 Key opinion leaders

13.5 Primary research – prescriber survey

13.6 About the authors

13.6.1 Analyst

13.6.2 Therapy Area Director

13.6.3 Epidemiologist

13.6.4 Managing Epidemiologist

13.6.5 Vice President of Disease Analysis and Intelligence

13.6.6 Global Head and EVP of Healthcare Operations and Strategy

Contact Us

Table

Table 1: PD: key metrics in the 7MM

Table 2: Modified HY scale of PD symptoms

Table 3: Movement Disorder Society-Sponsored Revision of the Unified PD Rating Scale (MDS-UPDRS), 2019

Table 4: Risk factors and comorbidities of PD

Table 5: Treatment guidelines for PD

Table 6: PD market – global drivers and barriers, 2019–29

Table 7: Key events impacting sales for PD in the US, 2019–29

Table 8: PD market – drivers and barriers in the US, 2019–29

Table 9: Key events impacting sales for PD in the 5EU, 2019–29

Table 10: PD market – drivers and barriers in the 5EU, 2019–29

Table 11: Key events impacting sales for PD in Japan, 2019–29

Table 12: PD market – drivers and barriers in Japan, 2019–29

Table 13: High-prescribing physicians (non-KOLs) surveyed, by country

Figures

Figure 1: Global sales forecast by country for PD in 2019 and 2029

Figure 2: Analysis of the Company Portfolio Gap in PD During the Forecast Period

Figure 3: 7MM, diagnosed prevalence (%) of PD, both sexes, ages ≥18 years, 2019

Figure 4: 7MM, sources used and not used to forecast the diagnosed prevalent cases of PD

Figure 5: 7MM, sources used to forecast the diagnosed prevalent cases of PD segmented by HY clinical staging

Figure 6: 7MM, diagnosed prevalent cases of PD, both sexes, N, ages ≥18 years, 2019

Figure 7: 7MM, diagnosed prevalent cases of PD by sex, N, ages ≥18 years, 2019

Figure 8: 7MM, diagnosed prevalent cases of PD by age, N, both sexes, 2019

Figure 9: 7MM, diagnosed prevalent cases of PD by HY clinical staging, N, both sexes, ages ≥18 years, 2019

Figure 10: 7MM, diagnosed prevalent cases of PD by type, N, both sexes, ages ≥18 years, 2019

Figure 11: Treatment algorithm for PD patients

Figure 12: Unmet needs and opportunities in PD

Figure 13: Pharmacokinetics of levodopa

Figure 14: Overview of the development pipeline in PD

Figure 15: Key late-stage trials for the promising pipeline agents that GlobalData expects to be licensed for PD in the 7MM during the forecast period

Figure 16: Competitive assessment of the pipeline levodopa therapies benchmarked against the SOC, Sinemet

Figure 17: Competitive assessment of the pipeline dopamine agonist drugs benchmarked against the SOC, Requip XL

Figure 18: Competitive assessment of blarcamesine benchmarked against the SOC, Nuplazid

Figure 19: Competitive assessment of the pipeline non-levodopa drugs benchmarked against the SOC, Azilect

Figure 20: Competitive assessment of the pipeline levodopa-induced dyskinesia drugs benchmarked against the SOC, Gocovri (amantadine ER)

Figure 21: Analysis of the company portfolio gap in PD during the forecast period (2019–29)

Figure 22: Global (7MM) sales forecast by country for PD in 2019 and 2029

Figure 23: Sales forecast by class for PD in the US in 2019 and 2029

Figure 24: Sales forecast by class for PD in the 5EU in 2019 and 2029

Figure 25: Sales forecast by class for PD in Japan in 2019 and 2029

Frequently asked questions

Parkinson’s Disease in Major Markets, Disease Management, Epidemiology, Pipeline Assessment, Unmet Needs and Drug Forecast 2029 standard reports
Currency USD
$10,995

Can be used by individual purchaser only

Most Popular
$21,990

Can be shared by unlimited users within one corporate location e.g. a regional office

$32,985

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Add to Basket

Undecided about purchasing this report?

Enquire Before Buying Request a Free Sample

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

Sample Report

Parkinson’s Disease in Major Markets, Disease Management, Epidemiology, Pipeline Assessment, Unmet Needs and Drug Forecast 2029 was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:

  • Assess the relevance of the report
  • Evaluate the quality of the report
  • Justify the cost

Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.

Below is a sample report to understand what you are buying

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

 Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

 Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

 Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

 Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

 Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

 Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

 Senior Account Manager, TSYS

Related reports

View more Parkinson's Disease reports
Pharmaceuticals
New
New Drug Approvals and Their Contract Manufacture - 2024 Edition
$4,995 | April 2024
Pharmaceuticals
New
Methicillin-Resistant Staphylococcus aureus (MRSA) Epidemiology Analysis and Forecast to 2033
$3,995 | April 2024
Pharmaceuticals
New
Antibody-Drug Conjugates (ADC) Overview, Industry Trends, Marketed and Pipeline Products,…
$6,995 | March 2024
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Parkinson’s Disease in Major Markets, Disease Management, Epidemiology, Pipeline Assessment, Unmet Needs and Drug Forecast 2029 in real time.

  • Access a live Parkinson’s Disease in Major Markets, Disease Management, Epidemiology, Pipeline Assessment, Unmet Needs and Drug Forecast 2029 dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.
Tell me more